VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services
VolitionRx has entered a co-marketing agreement with Hologic to promote its Nu.Q® Discover epigenetic profiling service, expanding access to pharmaceutical and academic researchers in a market valued at $200 million annually.
